Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a...

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• The survival benefit of abciximab in acute myocardial infarction (AMI) treated with routine infarct artery stenting remains unclear.
• Further research is needed to define the impact of abciximab on major adverse cardiac events (MACE) in this patient population.

Purpose of the Study:

• To evaluate the effect of abciximab on 1-year survival in patients with AMI undergoing routine infarct artery stenting.
• To assess the impact of abciximab on other major adverse cardiac events, including reinfarction and target vessel revascularization.

Main Methods:

• The Abciximab and Carbostent Evaluation (ACE) Trial was an unblinded, randomized, controlled trial.
• Patients with AMI undergoing routine infarct artery stent implantation received either abciximab or placebo.

Main Results:

• One-year survival was significantly higher in the abciximab group (95+/-2%) compared to the stent-alone group (88+/-2%) (P=0.017).
• The reinfarction rate was substantially lower with abciximab (1%) versus stent-alone (6.0%).
• No significant difference was observed in target vessel revascularization rates between the groups.

Conclusions:

• Adjunctive abciximab therapy improves 1-year survival in patients with acute myocardial infarction undergoing routine infarct artery stenting.
• Abciximab significantly reduces the risk of reinfarction in this clinical setting.
• The routine use of abciximab is beneficial for improving outcomes in AMI patients treated with infarct artery stenting.